{"filings":[{"id":1059236,"accession_number":"0001493152-26-028747","cik":1829247,"company_name":"BullFrog AI Holdings, Inc.","ticker":"BFRG","form_type":"8-K","filed_at":"2026-06-15T21:30:44+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"BullFrog AI raises CEO salary to $600K, target bonus up to 50% of base","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Vininder Singh's base salary increased from $400K to $600K, effective June 11, 2026.","Target annual bonus set at max 50% of current base salary.","Committee cited market data and Singh's contributions to strategic objectives.","Annual meeting: all four director nominees elected, auditor M&K CPAs ratified for FY2026.","42.06% of shares voted (~7.8M); no other proposals submitted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12478530.416725527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95936,"accession_number":"0001493152-26-018458","cik":1829247,"company_name":"BullFrog AI Holdings, Inc.","ticker":"BFRG","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BullFrog AI regains Nasdaq minimum stockholders' equity compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on April 21, 2026 confirming compliance with $2.5M minimum equity requirement.","Compliance achieved through sales under ATM and equity-line-of-credit facilities.","Subject to mandatory one-year panel monitor; any future non-compliance could lead to delisting without grace period.","CEO cites March commercial agreement with top 5 pharma as validation and cash runway extended into late 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12478530.416725527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95935,"accession_number":"0001493152-26-018365","cik":1829247,"company_name":"BullFrog AI Holdings, Inc.","ticker":"BFRG","form_type":"8-K","filed_at":"2026-04-21T23:59:59+00:00","items":["5.08","9.01"],"status":"ready","headline":"BullFrog AI sets June 11, 2026 annual meeting; shareholder proposal deadline April 29","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board established June 11, 2026 as date of the 2026 Annual Meeting of Stockholders.","Because meeting is over 30 days before anniversary of 2025 meeting, shareholder proposals and nominations due by April 29, 2026.","Notices must be sent to Secretary at 325 Ellington Blvd, Unit 317, Gaithersburg, MD 20878.","Proposals must also comply with Bylaws, SEC Rule 14a-19(b), and Nevada law."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":12478530.416725527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95934,"accession_number":"0001493152-26-016378","cik":1829247,"company_name":"BullFrog AI Holdings, Inc.","ticker":"BFRG","form_type":"8-K","filed_at":"2026-04-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BullFrog AI secures first commercial agreement with top 5 pharma; runway into late 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First commercial feasibility agreement with a top 5 global pharma for bfLEAP platform in MDD (market >$8B).","Financing in late March 2026 provides runway into late 2027; stockholders' equity >$2.5M meets Nasdaq standard.","Launched bfARENAS platform in March 2026, completing end-to-end AI platform for pharma R&D.","Ongoing Lieber Institute collaboration grants access to >2,800 human brain samples for neuropsychiatric targets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12478530.416725527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95933,"accession_number":"0001493152-26-014595","cik":1829247,"company_name":"BullFrog AI Holdings, Inc.","ticker":"BFRG","form_type":"8-K","filed_at":"2026-04-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BullFrog AI raises $3.45M, now believes it meets Nasdaq equity requirement; avoids delisting","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Raised aggregate net proceeds of at least $3.45M from ATM sales and equity line of credit facility.","Company now believes stockholders' equity exceeds $2.5M, regaining compliance with Nasdaq Listing Rule 5550(b)(1).","Previously received Nasdaq deficiency notice on Aug 21, 2025, and had requested a hearing before the Nasdaq Panel.","Hearing request had stayed any suspension or delisting action; company expects to resolve the listing deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12478530.416725527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109375,"accession_number":"0001493152-26-013684","cik":1829247,"company_name":"BullFrog AI Holdings, Inc.","ticker":"BFRG","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"BullFrog AI signs feasibility agreement with top-5 pharma for MDD target discovery","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement with top-5 global pharma (by 2025 revenue) for bfLEAP platform to identify novel drug targets in major depressive disorder (MDD).","One-year feasibility deal with milestone payments upon delivery of deliverables; client gets exclusive three-year option on a selected final target.","MDD market valued >$8B in 2025, expected ~$11B by 2032, per Stellar Market Research.","CEO Vin Singh calls it 'strong, high-quality validation' and expects the relationship to expand across other R&D areas.","Agreement filed as exhibit; termination clauses allow 30-day notice for no-cause termination from client."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12478530.416725527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109374,"accession_number":"0001493152-26-007656","cik":1829247,"company_name":"BullFrog AI Holdings, Inc.","ticker":"BFRG","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"BullFrog AI receives Nasdaq delisting notice for failing equity requirement; will request hearing","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified BullFrog AI on Feb 19, 2026 that it failed to meet extension terms for the $2.5M stockholders' equity requirement.","Securities are subject to delisting unless company timely requests a hearing before the Nasdaq Hearings Panel.","Company intends to request a hearing and present details of its compliance plan, seeking additional time.","Delisting could impair trading liquidity, price, and the company's ability to raise capital.","No assurance that the Panel will grant additional time or that compliance will be achieved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12478530.416725527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109373,"accession_number":"0001493152-26-007142","cik":1829247,"company_name":"BullFrog AI Holdings, Inc.","ticker":"BFRG","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"BullFrog AI receives Nasdaq deficiency notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified BullFrog AI on Feb 10, 2026 that common stock bid closed below $1.00 for 30 consecutive business days.","Company has 180 calendar days, until August 10, 2026, to regain compliance with Minimum Bid Price Requirement.","If not cured, company may qualify for second 180-day period by meeting other Nasdaq Capital Market standards and effecting reverse stock split.","Failure to regain compliance could lead to delisting; company will monitor and assess available options.","No immediate impact on listing; shares continue trading under BFRG and BFRGW on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12478530.416725527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125847,"accession_number":"0001493152-25-029636","cik":1829247,"company_name":"BullFrog AI Holdings, Inc.","ticker":"BFRG","form_type":"8-K","filed_at":"2025-12-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BullFrog AI details 2025 progress, pharma partnerships, and 2026 catalysts","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Annual cash burn ~$6.2M; $10M equity line and ATM provide financing flexibility.","Multiple advanced pharma discussions for out-licensing or discovery collaborations with upfront/milestone payments.","Sygnature Discovery collaboration expected to generate revenue through 2028; sales kickoff in Sept 2025.","Eleison data from late-stage oncology collaboration accepted for ASCO GI Cancers Symposium Jan 9, 2026.","Launched bfPREP data prep tool; reduces data prep from months to days, enabling earlier engagement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12478530.416725527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125846,"accession_number":"0001493152-25-019360","cik":1829247,"company_name":"BullFrog AI Holdings, Inc.","ticker":"BFRG","form_type":"8-K","filed_at":"2025-10-24T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"BullFrog AI stockholders approve reverse stock split and 750,000 share increase to equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved reverse stock split at ratio between 1:2 and 1:15, with Board discretion on final ratio.","Approved issuance of 20%+ of outstanding common stock to Lincoln Park Capital Fund under purchase agreement.","Approved amendment to 2022 equity plan increasing share reserve by 750,000 (from 900k to 1.65M pre-split).","Special Meeting held Oct 22, 2025; 56.02% of shares represented; all proposals passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12478530.416725527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125845,"accession_number":"0001493152-25-017599","cik":1829247,"company_name":"BullFrog AI Holdings, Inc.","ticker":"BFRG","form_type":"8-K","filed_at":"2025-10-09T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"BullFrog AI receives Nasdaq extension until Feb 17, 2026 to meet equity requirement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq granted BullFrog AI an extension until Feb 17, 2026 to regain compliance with $2.5M minimum stockholders' equity requirement.","Company received initial deficiency notice on Aug 21, 2025 and submitted a compliance plan in late September 2025.","If equity shortfall not cured by deadline, common stock (BFRG) and warrants (BFRGW) face delisting from Nasdaq.","Company intends to take reasonable measures but cannot assure regaining compliance by the deadline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12478530.416725527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142600,"accession_number":"0001493152-25-014653","cik":1829247,"company_name":"BullFrog AI Holdings, Inc.","ticker":"BFRG","form_type":"8-K","filed_at":"2025-09-23T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Bullfrog AI reduces stockholder quorum to 33.33% and announces 2025 annual meeting results","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Quorum for stockholder meetings reduced to 33.33% of shares outstanding, effective September 18, 2025.","Four directors elected: William Enright, Jason D. Hanson, R. Donald Elsey, Vininder Singh.","M&K CPAs ratified as independent auditor for fiscal 2025 with 5,885,223 votes for, 98,872 against.","Annual meeting had 59.50% of shares represented, totaling 5,999,172 votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":12478530.416725527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142599,"accession_number":"0001493152-25-013729","cik":1829247,"company_name":"BullFrog AI Holdings, Inc.","ticker":"BFRG","form_type":"8-K","filed_at":"2025-09-16T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"BullFrog AI secures $10M equity line with Lincoln Park Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered purchase agreement with Lincoln Park Capital Fund for up to $10M of common stock over 36 months.","Company may sell shares at its discretion from time to time; Lincoln Park obligated to buy subject to conditions.","Issued 147,682 commitment shares to Lincoln Park as consideration for the facility.","Exchange cap of 2,048,936 shares (19.99% of outstanding) unless stockholder approval or average price condition met.","Net proceeds expected for working capital; no short selling by Lincoln Park during term."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12478530.416725527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142598,"accession_number":"0001641172-25-025710","cik":1829247,"company_name":"BullFrog AI Holdings, Inc.","ticker":"BFRG","form_type":"8-K","filed_at":"2025-08-27T23:59:59+00:00","items":["3.01","5.02"],"status":"ready","headline":"BullFrog AI receives Nasdaq deficiency letter for equity shortfall; issues 267,842 share retention awards","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders' equity of $2,188,110 as of June 30, 2025 falls below Nasdaq's $2.5M minimum requirement.","Company has 45 days to submit a compliance plan; possible 180-day extension if plan accepted.","Board granted refresh equity awards totaling 267,842 shares to executives and directors.","Awards consist of 33% immediate vesting stock and 67% RSUs vesting 50% each on Sep 1, 2026 and Sep 1, 2027.","Existing stock options are significantly underwater; awards intended for retention during critical period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12478530.416725527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160676,"accession_number":"0001641172-25-014872","cik":1829247,"company_name":"BullFrog AI Holdings, Inc.","ticker":"BFRG","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BullFrog AI enters collaboration with Sygnature Discovery targeting $15M-$30M revenue through 2028","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Collaboration with UK-based CRO Sygnature Discovery to offer BullFrog Data Networks to global biopharma clients.","Expected revenue for BullFrog AI from the collaboration: $15-$30 million through 2028.","BullFrog Data Networks is powered by its bfLEAP engine, aimed at accelerating target discovery and drug development.","CEO Vin Singh calls it a major commercial milestone; Sygnature CTO Stuart Onions confirms platform complements their offerings.","No upfront or milestone payments disclosed; revenue projections are forward-looking."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12478530.416725527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160675,"accession_number":"0001641172-25-006356","cik":1829247,"company_name":"BullFrog AI Holdings, Inc.","ticker":"BFRG","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Bullfrog AI enters $20M at-the-market equity distribution agreement with BTIG","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement with BTIG to sell up to $20M of common stock via ATM offerings at market prices.","Company pays 3% commission; no obligation to sell any shares; BTIG uses commercially reasonable efforts.","Shares offered under existing S-3 shelf (Reg. No. 333-281341) effective August 21, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12478530.416725527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178891,"accession_number":"0001493152-25-008518","cik":1829247,"company_name":"BullFrog AI Holdings, Inc.","ticker":"BFRG","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bullfrog AI enters collaboration with Eleison to optimize Phase 3 pancreatic cancer trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Collaboration announced Feb 27, 2025; Bullfrog AI to apply bfLEAP platform to Eleison's glufosfamide Phase 3 trial.","Bullfrog Data Networks will analyze safety signals and extract predictive biomarkers from prior and ongoing studies.","Eleison's ongoing glufosfamide Phase 3 trial targets second-line pancreatic cancer; expected completion in 2027.","Financial terms of the agreement were not disclosed.","Partnership also covers Eleison's pipeline programs ILC (lung cancer) and DBD (brain cancers)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12478530.416725527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195562,"accession_number":"0001493152-24-052248","cik":1829247,"company_name":"BullFrog AI Holdings, Inc.","ticker":"BFRG","form_type":"8-K","filed_at":"2024-12-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bullfrog AI CEO highlights AI platform advances, LIBD collaboration, BF-114 progress, $8.83M raised in 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["bfLEAP platform enhanced with generative and causal AI exclusively licensed from Johns Hopkins APL, enabling explainable AI for target discovery and drug repositioning.","LIBD collaboration identified novel drug targets for schizophrenia, bipolar disorder, and major depressive disorder; advanced pharma discussions underway.","BF-114 demonstrated potential in obesity, MASLD, and HCC; published in Cell Reports. Liver disease market projected to exceed $36.5B by 2030.","Raised $8.83M from two equity offerings in 2024, bolstering cash position for growth initiatives and working capital.","Strengthened IP with Australian patent for BF-223 (oncology, glioblastoma); added Dr. Chittenden as CSO and Dr. Baldoni to SAB."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12478530.416725527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195561,"accession_number":"0001493152-24-050448","cik":1829247,"company_name":"BullFrog AI Holdings, Inc.","ticker":"BFRG","form_type":"8-K","filed_at":"2024-12-17T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Bullfrog AI appoints Josh Blacher as CFO; prior CFO Dane Saglio passed away from cancer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appoints Josh Blacher as CFO effective Dec 12, 2024 via consulting agreement with Danforth Advisors at $525/hour.","Former CFO Dane Saglio passed away due to cancer; Blacher replaces him.","Blacher has served as CFO at Predictive Oncology, Rampart Bioscience, Excision BioTherapeutics, and others.","Blacher will focus on balance sheet strength, financial operations, and strategic initiatives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12478530.416725527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195560,"accession_number":"0001493152-24-049790","cik":1829247,"company_name":"BullFrog AI Holdings, Inc.","ticker":"BFRG","form_type":"8-K","filed_at":"2024-12-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Bullfrog AI CFO Dane Saglio passed away on Dec 7; successor search underway","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Dane Saglio died on December 7, 2024; had served since September 2021.","Board initiated succession search and plans to announce a replacement soon.","No interim CFO named; CEO Vininder Singh signed the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12478530.416725527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195559,"accession_number":"0001493152-24-041781","cik":1829247,"company_name":"BullFrog AI Holdings, Inc.","ticker":"BFRG","form_type":"8-K","filed_at":"2024-10-21T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Bullfrog AI raises $3.13M in registered direct offering and private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 1,565,000 shares (or pre-funded equivalents) at $2.00/share plus warrants for same number.","Gross proceeds $3.13M; warrants exercisable at $2.00 after 6 months, expire in 5 years.","Directors and officers locked up for 60 days from closing on Oct 21, 2024.","WallachBeth Capital acted as sole placement agent with 8% cash fee and 4% warrant coverage."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12478530.416725527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195558,"accession_number":"0001493152-24-041044","cik":1829247,"company_name":"BullFrog AI Holdings, Inc.","ticker":"BFRG","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bullfrog AI appoints GSK veteran Dr. John Baldoni to Scientific Advisory Board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Baldoni brings 40+ years of pharma experience, including 29 years at GSK as SVP of Platform and Technology Sciences.","He contributed to scores of commercial products and co-founded the ATOM consortium for AI-driven drug development.","CEO Vin Singh cited Baldoni's insights as key to guiding commercialization of the bfLEAP platform."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":12478530.416725527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195557,"accession_number":"0001493152-24-040526","cik":1829247,"company_name":"BullFrog AI Holdings, Inc.","ticker":"BFRG","form_type":"8-K","filed_at":"2024-10-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bullfrog AI publishes Cell Reports data supporting BF-114 for liver diseases; adds Dr. Lopa Mishra to advisory board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Study led by Dr. Lopa Mishra published in Cell Reports provides mechanistic evidence for BF-114 target β2-spectrin (SPTBN1 siRNA) in obesity, MASLD, MASH, and HCC.","Findings show reducing β2-spectrin can halt progression of MASLD and MASH and reduce liver damage in animal models.","Dr. Lopa Mishra, a globally recognized liver disease expert, joined Bullfrog AI's Scientific Advisory Board to guide BF-114 development.","Bullfrog AI will use its bfLEAP AI platform to analyze single-cell data from animal models and human patients for further mechanistic insights.","BF-114 is an siRNA targeting SPTBN1, aimed at treating obesity-related liver diseases with high unmet need."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12478530.416725527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211825,"accession_number":"0001493152-24-038110","cik":1829247,"company_name":"BullFrog AI Holdings, Inc.","ticker":"BFRG","form_type":"8-K","filed_at":"2024-09-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Bullfrog AI shareholders elect four directors and ratify auditor at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting held Sept 20, 2024; 63.02% quorum (4,947,894 shares represented).","Elected directors: William Enright, Jason D. Hanson, R. Donald Elsey, Vininder Singh (each ~2.9M FOR, 0 AGAINST).","Ratified M&K CPAs as auditor for FY2024: 4,784,257 FOR, 103,756 AGAINST, 59,881 ABSTAIN."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":12478530.416725527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211824,"accession_number":"0001493152-24-029076","cik":1829247,"company_name":"BullFrog AI Holdings, Inc.","ticker":"BFRG","form_type":"8-K","filed_at":"2024-07-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BullFrog AI collaboration with LIBD identifies bipolar disorder molecular pathways, potential drug targets","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Six of 68 gene clusters from LIBD brain dataset significantly enriched, pinpointing gene networks involved in bipolar disorder.","Notable findings in Dentate Gyrus (memory/cognition) and Dorsolateral Prefrontal Cortex (executive function).","Analysis suggests dysregulation of pro-inflammatory pathways; novel pathways and putative drivers identified.","Company engaging with pharmaceutical partners for drug target discovery deals.","BullFrog AI used its bfLEAP platform and causal AI strategy in collaboration with LIBD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12478530.416725527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230598,"accession_number":"0001493152-24-020150","cik":1829247,"company_name":"BullFrog AI Holdings, Inc.","ticker":"BFRG","form_type":"8-K","filed_at":"2024-05-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bullfrog AI and Lieber Institute identify novel drug targets for neuropsychiatric disorders","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Identified dozens of patient clusters for depression, schizophrenia, and bipolar disorder using bfLEAP AI platform.","Key genes pinpointed for each cluster as potential drug targets; now applying Causal AI for validation.","Engagement initiated with pharmaceutical companies to secure strategic partnerships in coming quarters.","Collaboration leverages LIBD's brain data from over 2,800 samples under a three-year exclusive agreement.","Findings build on September 2023 partnership and January 2024 stratification results."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12478530.416725527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230597,"accession_number":"0001493152-24-014015","cik":1829247,"company_name":"BullFrog AI Holdings, Inc.","ticker":"BFRG","form_type":"8-K","filed_at":"2024-04-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bullfrog AI CSO to present at Quantum Computing Symposium on April 15","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CSO Tom Chittenden to present at Bio-IT World Conference in Boston on April 15, 2024 at 1 pm ET.","Presentation titled 'Quantum Assisted AI/ML for Precision Medicine'.","Will cover quantum methods for deciphering complex disease patterns including multi-omics cancer data.","Presentation highlights potential of quantum computing to surpass traditional computational models."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":12478530.416725527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248969,"accession_number":"0001493152-24-009316","cik":1829247,"company_name":"BullFrog AI Holdings, Inc.","ticker":"BFRG","form_type":"8-K","filed_at":"2024-03-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BullFrog AI releases fireside chat recording; details brain sample analysis collaboration with Lieber Institute","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Fireside chat on March 5, 2024, featuring CEO Vin Singh and Lieber Institute CEO Daniel Weinberger.","Collaboration uses over 2,800 brain samples to study schizophrenia, bipolar disorder, major depressive disorder via graph analytics.","Subjects clustered based on biological data alone, independent of behavioral diagnoses, uncovering potential subtypes.","Findings may enhance understanding of psychiatric conditions and lead to targeted treatments and revenue-generating partnerships.","Recording accessible via YouTube link provided in press release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":12478530.416725527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248968,"accession_number":"0001493152-24-007776","cik":1829247,"company_name":"BullFrog AI Holdings, Inc.","ticker":"BFRG","form_type":"8-K","filed_at":"2024-02-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bullfrog AI Appoints Dr. Thomas W. Chittenden as Chief Scientific Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Chittenden appointed CSO effective February 26, 2024.","Previously served as CSO and President of R&D at BioAI Health.","Also founded AI/SciML initiative at HiberCell and consulted at Harvard Medical School.","Will lead scientific strategy to advance Bullfrog AI's bfLEAP™ AI drug discovery platform."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12478530.416725527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248967,"accession_number":"0001493152-24-005563","cik":1829247,"company_name":"BullFrog AI Holdings, Inc.","ticker":"BFRG","form_type":"8-K","filed_at":"2024-02-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bullfrog AI CEO to discuss early collaboration findings in fireside chat on March 5, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Vin Singh and LIBD's Daniel R. Weinberger will host a RedChip fireside chat on March 5, 2024 at 4:15 p.m. ET.","Collaboration with Lieber Institute for Brain Development used over 2,800 brain samples to stratify expression data.","Findings cluster subjects by biology alone, uncovering subtypes across schizophrenia, bipolar, and major depressive disorder.","Potential to enable targeted treatments and open revenue-generating pharma partnerships.","Company's bfLEAP AI platform is used to analyze biological and clinical data for drug development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":12478530.416725527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248966,"accession_number":"0001493152-24-005096","cik":1829247,"company_name":"BullFrog AI Holdings, Inc.","ticker":"BFRG","form_type":"8-K","filed_at":"2024-02-06T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Bullfrog AI closes $5.7M public offering of stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of approx $5.7M from sale of 1,507,139 shares (or pre-funded warrants) and accompanying warrants.","Pricing at $3.782 per share; underwriters granted 45-day over-allotment option for 226,071 additional shares.","Net proceeds to be used for working capital and general corporate purposes.","Offering closed Feb 5, 2024, after satisfying all customary closing conditions.","WallachBeth Capital acted as sole book-running manager for the offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12478530.416725527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248965,"accession_number":"0001493152-24-003837","cik":1829247,"company_name":"BullFrog AI Holdings, Inc.","ticker":"BFRG","form_type":"8-K","filed_at":"2024-01-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bullfrog AI appoints Dr. Gwenn Smith and Dr. Jeremiah Wala as scientific advisors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Gwenn Smith (Johns Hopkins) adds expertise in brain imaging, neuropsychiatry, and Alzheimer's disease.","Dr. Jeremiah Wala (Dana-Farber) brings computational biology and oncology focus on structural variation in cancer genomes.","Advisors will support Bullfrog AI's AI-driven drug development platform bfLEAP and its partnership with Lieber Institute.","Appointments effective January 26, 2024; both will guide the company's mission to develop breakthrough therapies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":12478530.416725527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248964,"accession_number":"0001493152-24-002575","cik":1829247,"company_name":"BullFrog AI Holdings, Inc.","ticker":"BFRG","form_type":"8-K","filed_at":"2024-01-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bullfrog AI collaboration yields potentially groundbreaking stratification of brain expression data","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Early results from collaboration with Lieber Institute for Brain Development successfully stratified brain expression data from over 2,800 samples.","Clustered subjects based solely on biological data, independent of behavioral diagnoses, revealing biological subtypes within disorders.","CEO Vin Singh says findings could pave way for revenue-generating partnerships with pharmaceutical companies.","Collaboration announced Sep 2023 gave Bullfrog AI exclusive access to LIBD's brain data for commercialization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":12478530.416725527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248963,"accession_number":"0001493152-24-002348","cik":1829247,"company_name":"BullFrog AI Holdings, Inc.","ticker":"BFRG","form_type":"8-K","filed_at":"2024-01-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BullFrog AI receives Australian patent for mebendazole prodrugs including BF-223","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Australian Patent No. 2019216757 issued for novel prodrugs of mebendazole to treat cancers.","Follows U.S. Patent No. 11,712,435 issued July 2023; additional territories expected.","Patented compounds show improved solubility and oral bioavailability versus parent mebendazole.","BF-223, a key pipeline asset, previously showed anticancer activity in a glioblastoma animal model.","CEO Vin Singh says patent strengthens IP protection and supports partnering strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12478530.416725527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266503,"accession_number":"0001493152-23-046489","cik":1829247,"company_name":"BullFrog AI Holdings, Inc.","ticker":"BFRG","form_type":"8-K","filed_at":"2023-12-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bullfrog AI highlights 2023 achievements: $8.4M IPO, first revenue, key partnerships","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed $8.4M IPO listing on Nasdaq in 2023; maintained low burn rate quarter to quarter.","Recorded first earned revenue in Q3 2023; transition to commercial operations.","Entered exclusive partnership with Lieber Institute for Brain Development for neuropsychiatric drug discovery.","Demonstrated efficacy of oncology drug candidates BF-223 and BF-222 in glioblastoma animal model; patent issued for BF-223.","Identified three novel colorectal cancer targets via JCVI partnership; market $11.5B in 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12478530.416725527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266502,"accession_number":"0001493152-23-037840","cik":1829247,"company_name":"BullFrog AI Holdings, Inc.","ticker":"BFRG","form_type":"8-K","filed_at":"2023-10-20T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Bullfrog AI enters commercial agreement with Lieber Institute to commercialize AI-derived brain data products","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered commercial agreement with Lieber Institute for Brain Development to commercialize AI/ML products from LIBD brain data.","BFAI granted exclusive worldwide license to develop, sell Licensed Products in drug development field (therapeutic, target ID, patient selection).","BFAI to pay LIBD royalty on Net Sales (rates redacted); exclusivity ends if no First Commercial Sale within 2 years of listing.","LIBD may change license to non-exclusive after 3 years from First Commercial Sale, adjusting royalty rate.","LIBD receives Licensed Products free for internal research; if LIBD commercializes, pays BFAI 70% of Net Sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":12478530.416725527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266501,"accession_number":"0001493152-23-035753","cik":1829247,"company_name":"BullFrog AI Holdings, Inc.","ticker":"BFRG","form_type":"8-K","filed_at":"2023-10-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bullfrog AI identifies 3 novel colorectal cancer targets via bfLEAP platform; validation with JCVI planned","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["14 candidates over-expressed in colon tumors identified using TCGA data; 3 are novel, 6 near-novel.","bfLEAP platform reduced candidate list from >3,000 traditional analysis to 14 actionable targets.","Target validation to be conducted with J. Craig Venter Institute under existing collaboration.","Colorectal cancer market valued at $11.5B in 2022, projected CAGR 4.7% through 2030."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12478530.416725527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283741,"accession_number":"0001493152-23-033671","cik":1829247,"company_name":"BullFrog AI Holdings, Inc.","ticker":"BFRG","form_type":"8-K","filed_at":"2023-09-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bullfrog AI files 8-K on press release and investor data for preclinical study; details unavailable","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed under Item 7.01; press release and investor presentation attached as exhibits.","Exhibit 99.1 press release and Exhibit 99.2 investor materials reference a recent preclinical study.","Specific study results, data, or forward-looking statements not available in the provided text.","No financial figures, guidance, or material operational changes disclosed in the filing body.","Investors need to review full exhibits for substantive information."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":12478530.416725527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283740,"accession_number":"0001493152-23-033140","cik":1829247,"company_name":"BullFrog AI Holdings, Inc.","ticker":"BFRG","form_type":"8-K","filed_at":"2023-09-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bullfrog AI files 8-K with press release; no specific details available","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Press release attached as Exhibit 99.1; full text not included in provided document.","Filing under Regulation FD; no material financial or operational data extracted.","Company trades on Nasdaq under BFRG and BFRGW."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":12478530.416725527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283739,"accession_number":"0001493152-23-032658","cik":1829247,"company_name":"BullFrog AI Holdings, Inc.","ticker":"BFRG","form_type":"8-K","filed_at":"2023-09-14T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Bullfrog AI enters exclusive data partnership with Lieber Institute for Brain Development","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Agreement signed Sep 8, 2023 gives Bullfrog AI access to LIBD's transcriptomic, genomic, epigenomic, and imaging brain data.","One-year exclusive, fully paid royalty-free license to mine data using bfLEAP platform.","Parties to negotiate future commercialization agreement with revenue split.","LIBD is a leading independent nonprofit focused on brain development and mental health disorders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12478530.416725527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283738,"accession_number":"0001493152-23-025446","cik":1829247,"company_name":"BullFrog AI Holdings, Inc.","ticker":"BFRG","form_type":"8-K","filed_at":"2023-07-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BullFrog AI announces USPTO issuance of patent for novel mebendazole prodrugs for cancer treatment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["USPTO to issue Patent No. 11,712,435 on Aug 1, 2023, protecting novel prodrugs of mebendazole with improved solubility and oral bioavailability.","This is the first patent from IP licensed from Johns Hopkins University in Oct 2022; BullFrog AI holds exclusive worldwide royalty-bearing rights.","CEO Vin Singh says prodrugs address key difficulty in evaluating mebendazole for oncology, enhancing potential for glioblastoma and other cancers.","Company intends to work with strategic partners to monetize the asset for clinical development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12478530.416725527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283737,"accession_number":"0001493152-23-024169","cik":1829247,"company_name":"BullFrog AI Holdings, Inc.","ticker":"BFRG","form_type":"8-K","filed_at":"2023-07-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bullfrog AI appoints Enrique García-Rivera as VP of Artificial Intelligence","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Enrique García-Rivera, Ph.D., as Vice President of Artificial Intelligence to enhance bfLEAP AI platform.","Prior roles include leading clinical applications at ROME Therapeutics and drug discovery platforms at nference.","He previously identified a novel kinase dependency in synovial sarcomas at the Broad Institute of Harvard and MIT.","CEO Vin Singh stated the appointment will strengthen AI-driven drug development and personalized therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12478530.416725527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303304,"accession_number":"0001493152-23-020660","cik":1829247,"company_name":"BullFrog AI Holdings, Inc.","ticker":"BFRG","form_type":"8-K","filed_at":"2023-06-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BullFrog AI CEO Vin Singh to present at Gujarati Physicians Convention 2023 on June 10","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Vin Singh will present at the Gujarati Physicians Convention in Atlantic City, NJ on June 10, 2023 at 11 a.m. ET.","Convention theme is 'Futuristic Medicine'; over 1,000 physicians expected to attend.","Event is part of Continuing Medical Education (CME) hosted by Baroda Medical College Alumni Association."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":12478530.416725527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303303,"accession_number":"0001493152-23-020073","cik":1829247,"company_name":"BullFrog AI Holdings, Inc.","ticker":"BFRG","form_type":"8-K","filed_at":"2023-06-05T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Bullfrog AI expands APL license to enhance bfLEAP AI platform capabilities","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Expanded worldwide license with Johns Hopkins APL for patented technology powering bfLEAP AI platform.","New multivariate diffuse indexing algorithm enables probabilistic modeling on mixed categorical/numerical data.","Graph algorithms reorganized into three repositories with ~80 runnable analytics each for improved robustness.","Platform improvements aim to streamline drug development data analytics and reduce failure rates.","CEO Vin Singh states commitment to establishing Bullfrog AI as leader in AI-driven drug development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12478530.416725527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303302,"accession_number":"0001493152-23-019280","cik":1829247,"company_name":"BullFrog AI Holdings, Inc.","ticker":"BFRG","form_type":"8-K","filed_at":"2023-05-26T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Bullfrog AI regains Nasdaq listing compliance after filing late 10-Q","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency notice on May 23 for late Q1 2023 10-Q filing.","Filed Form 10-Q on May 22, 2023, prior to the notice.","Company now in full compliance with Nasdaq Listing Rule 5250(c)(1).","No immediate effect on listing; shares continue trading on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":12478530.416725527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303301,"accession_number":"0001493152-23-013528","cik":1829247,"company_name":"BullFrog AI Holdings, Inc.","ticker":"BFRG","form_type":"8-K","filed_at":"2023-04-25T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Bullfrog AI receives Nasdaq deficiency notice for late 10-K, files and regains compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency letter on April 19, 2023 for failing to timely file Form 10-K (Rule 5250(c)(1)).","Company filed the overdue 10-K on April 25, 2023, curing the deficiency and regaining compliance.","Deficiency letter had no immediate effect on listing of common stock (BFRG) or warrants (BFRGW).","CEO Vin Singh noted the delay was due to the first-time nature of the annual report filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":12478530.416725527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322916,"accession_number":"0001493152-23-005665","cik":1829247,"company_name":"BullFrog AI Holdings, Inc.","ticker":"BFRG","form_type":"8-K","filed_at":"2023-02-21T23:59:59+00:00","items":["1.01","5.02","8.01","9.01"],"status":"ready","headline":"Bullfrog AI raises ~$8.4M in underwritten public offering of units; appoints three independent directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$8.43M from sale of 1,297,318 units at $6.50/unit; each unit includes one share, one tradeable warrant (exercise $7.80), and one non-tradeable warrant (exercise $8.125).","Over-allotment of 306,818 warrants exercised; offering closed Feb 16, 2023; common stock and tradeable warrants began trading on Nasdaq Feb 15.","Don Elsey, William Enright, and Jason Hanson appointed as independent directors effective Feb 15, 2023; they will serve on audit, compensation, and nominating committees.","Lock-up agreements for six months for company, directors, officers, and certain stockholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12478530.416725527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}